Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Masami Iwasa, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Kumiko Kagawa, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Akishige Ikegame, MD, PhD, Daisuke Tsuji, PhD, Kohji Itoh, PhD, Masaki Ri, MD, PhD, Shinsuke Iida, MD, PhD, Yukimasa Shiotsu, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2012) 120 (21): 1839.

https://doi.org/10.1182/blood.V120.21.1839.1839

Published: 2012

Journal Articles

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Hirokazu Miki, MD, Masahiro Abe, MD, PhD, Kumiko Kagawa, MD, Asuka Oda, PhD, Hiroe Amou, PhD, Akishige Ikegame, PhD, Keiichiro Watanabe, DDS, Masahiro Hiasa, DDS, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ayako Nakano, MD, PhD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Yukimasa Shiotsu, PhD, Masaki Ri, MD, Shinsuke Iida, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 5104.

https://doi.org/10.1182/blood.V118.21.5104.5104

Published: 2011

Journal Articles

Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells

Ayako Nakano, MD, PhD, Masahiro Abe, MD, PhD, Daisuke Tsuji, PhD, Hirokazu Miki, MD, Akishige Ikegame, PhD, Shingen Nakamura, MD, Takeshi Harada, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Kohji Itoh, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 135.

https://doi.org/10.1182/blood.V118.21.135.135

Published: 2011

Journal Articles

Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment

Qu Cui, MD, Masahiro Abe, MD, PhD, Hirokazu Miki, MD, Shingen Nakamura, MD, Keiichiro Watanabe, DDS, Akishige Ikegame, Masahiro Hiasa, DDS, PhD, Ayako Nakano, MD, PhD, Takeshi Harada, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2010) 116 (21): 3025.

https://doi.org/10.1182/blood.V116.21.3025.3025

Published: 2010

Journal Articles

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

Shingen Nakamura, Masahiro Abe, Qu Cui, Ayako Nakano, Asuka Oda, Hiroe Amou, Akishige Ikegame, Takeshi Harada, Masahiro Hiasa, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Kenichiro Yata, Shuji Ozaki, Toshio Matsumoto

Blood (2009) 114 (22): 1823.

https://doi.org/10.1182/blood.V114.22.1823.1823

Published: 2009

Journal Articles

A Recombinant HLA Class I-Specific Single-Chain Fv Diabody Can Target Cancer Stem Cell-Like Side Population Cells in Multiple Myeloma.

Akishige Ikegame, Shuji Ozaki, Daisuke Tsuji, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Ayako Nakano, Kumiko Kagawa, Kyoko Takeuchi, Kenichiro Yata, Masahiro Abe, Kohji Itoh, Toshio Matsumoto

Blood (2009) 114 (22): 2799.

https://doi.org/10.1182/blood.V114.22.2799.2799

Published: 2009

NARROW

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells

Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

A Recombinant HLA Class I-Specific Single-Chain Fv Diabody Can Target Cancer Stem Cell-Like Side Population Cells in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells

Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

A Recombinant HLA Class I-Specific Single-Chain Fv Diabody Can Target Cancer Stem Cell-Like Side Population Cells in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only